The University of Hong Kong’s LKS Faculty of Medicine has made significant strides in understanding and managing Chronic Obstructive Pulmonary Disease (COPD), particularly in relation to its exacerbations. A recent study published in the journal Lung highlights the importance of assessing patients’ risk profiles through blood eosinophil counts and sputum analysis to personalize treatment strategies.
COPD, a prevalent chronic disease globally, is primarily caused by cigarette smoking and can lead to irreversible lung damage. Acute exacerbations of COPD can result in hospitalization and a rapid decline in lung function, emphasizing the need for prevention, early detection, and precise management.
The research team at HKUMed found that measuring blood eosinophil counts can help identify patients at risk of acute COPD exacerbations. By analyzing the variability of eosinophil levels between stable periods and exacerbations, a more accurate prediction of future exacerbations can be made. Additionally, sputum analysis for Pseudomonas aeruginosa colonization in airways can significantly elevate the risk of exacerbations, further emphasizing the importance of personalized treatment approaches.
The newly released Global Initiative for Chronic Obstructive Lung Disease Report 2026 introduces revised patient classification criteria, highlighting the importance of exacerbations in COPD management. Early identification of high-risk patients is crucial for developing effective therapeutic strategies.
Dr. Herbert Kwok Wang-chun, Clinical Assistant Professor at HKUMed, leads the research team’s efforts in COPD phenotyping and personalized treatment. Their multi-national multi-center study aims to refine personalized treatment strategies for COPD across the Asia-Pacific region.
By enhancing understanding of COPD and its exacerbations, the research team at HKUMed strives to improve the management of this treatable and preventable disease. Their findings on blood eosinophil counts and sputum analysis provide valuable insights for clinicians in developing tailored treatment plans for COPD patients.
For more information, the study titled “Differences in Blood Eosinophil Level During Stable Disease and During Exacerbation of COPD and Exacerbation Risks” can be accessed in the journal Lung. The University of Hong Kong continues to lead advancements in COPD research, aiming to improve patient outcomes and quality of life.
